Alaunos TherapeuticsTCRT
TCRT
About: Alaunos Therapeutics Inc is a clinical-stage cellular immuno-oncology company dedicated to the treatment of solid tumors through adoptive TCR-T cell therapy. It strikes cancer at its core by engineering cell therapies that target Neoantigens arising from genomic mutations.
Employees: 34
0
Funds holding %
of 6,809 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
3.14% less ownership
Funds ownership: 15.15% [Q2] → 12.0% (-3.14%) [Q3]
44% less funds holding
Funds holding: 50 [Q2] → 28 (-22) [Q3]
63% less capital invested
Capital invested by funds: $1.7M [Q2] → $623K (-$1.08M) [Q3]
85% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 26
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 24
Research analyst outlook
We haven’t received any recent analyst ratings for TCRT.
Financial journalist opinion
Neutral
InvestorPlace
1 year ago
Why Is Alaunos Therapeutics (TCRT) Stock Up 37% Today?
Alaunos Therapeutics (NASDAQ: TCRT ) stock is up on Monday despite a lack of news from the clinical-stage oncology-focused cell therapy company. There are no new press releases or filings with the Securities and Exchange Commission (SEC) that explain why the stock is up today.
Positive
InvestorPlace
1 year ago
Why Is Alaunos Therapeutics (TCRT) Stock Up 14% Today?
Alaunos Therapeutics (NASDAQ: TCRT ) stock is heading higher on Tuesday following the release of the clinical-stage oncology-focused cell therapy company's Q3 earnings report. The Alaunos Therapeutics earnings report starts with earnings per share of -4 cents.
Neutral
GlobeNewsWire
1 year ago
Alaunos Therapeutics Announces Third Quarter 2023 Financial Results, Phase 1 Clinical Data and Continued Exploration of Strategic Alternatives
HOUSTON, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), today announced financial results for the third quarter ended September 30, 2023. As previously announced, the Company is exploring strategic alternatives with Cantor Fitzgerald & Co. as its strategic advisor. Alaunos continues to reduce spend and cost-savings measures taken to date are expected to extend its cash runway into the second quarter of 2024.
Charts implemented using Lightweight Charts™